Premium
COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients
Author(s) -
Chakraborty Chiranjib,
Sharma Ashish Ranjan,
Bhattacharya Manojit,
Sharma Garima,
Lee SangSoo,
Agoramoorthy Govindasamy
Publication year - 2020
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.26078
Subject(s) - cytokine storm , tocilizumab , cytokine release syndrome , medicine , cytokine , receptor antagonist , immunology , covid-19 , interleukin 1 receptor antagonist , virology , interleukin 6 , antagonist , receptor , infectious disease (medical specialty) , disease , rheumatoid arthritis
COVID‐19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL‐6R) antagonist therapy for the COVID‐19 patients. Two humanized monoclonal antibodies are in clinical trial following IL‐6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL‐6R antagonists for the therapy of cytokine storm syndrome severe acute respiratory syndrome coronavirus 2 infected persons to enhance the therapeutic options for cytokine storm.